{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:17:48Z","timestamp":1790731068396,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.disamonth.2021.101304","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T17:32:35Z","timestamp":1640712755000},"page":"101304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Recent Advances in the Diagnosis and Management of Carcinoid Syndrome"],"prefix":"10.1016","volume":"68","author":[{"given":"Nagarjun","family":"Subash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishel Maria","family":"Papali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khatri Prashant","family":"Bahadur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaithanya","family":"Avanthika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharan","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijani","family":"Thannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meet","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Sudha","family":"Valisekka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.disamonth.2021.101304_bib0001","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2","article-title":"An analysis of 8305 cases of carcinoid tumors","volume":"79","author":"Modlin","year":"1997","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.disamonth.2021.101304_bib0002","doi-asserted-by":"crossref","first-page":"e490s","DOI":"10.6061\/clinics\/2018\/e490s","article-title":"Carcinoid syndrome: update on the pathophysiology and treatment","volume":"73","author":"Rubin de Celis Ferrari","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"issue":"4","key":"10.1016\/j.disamonth.2021.101304_bib0003","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1677\/erc.0.0100427","article-title":"Highlights of the biology of endocrine tumours of the gut and pancreas","volume":"10","author":"Rindi","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.disamonth.2021.101304_bib0004","series-title":"Histological Classification of Endocrine Tumours","first-page":"7","author":"Solcia","year":"2000"},{"issue":"4","key":"10.1016\/j.disamonth.2021.101304_bib0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.disamonth.2021.101304_bib0006","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11154-020-09547-8","article-title":"Serotonin pathway in carcinoid syndrome: clinical, diagnostic, prognostic and therapeutic implications","volume":"21","author":"Fanciulli","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.disamonth.2021.101304_bib0007","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000382053","article-title":"Clinical syndromes related to gastrointestinal neuroendocrine neoplasms","volume":"44","author":"Boutzios","year":"2015","journal-title":"Front Horm Res"},{"issue":"4","key":"10.1016\/j.disamonth.2021.101304_bib0008","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid heart disease: from pathophysiology to treatment\u2013'something in the way it moves'","volume":"101","author":"Grozinsky-Glasberg","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.disamonth.2021.101304_bib0009","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.1964.03860070072004","article-title":"The carcinoid crisis","volume":"114","author":"Kahil","year":"1964","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.disamonth.2021.101304_bib0010","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.disamonth.2021.101304_bib0011","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.disamonth.2021.101304_bib0012","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bpg.2012.12.003","article-title":"Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances","volume":"26","author":"Ito","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.disamonth.2021.101304_bib0013","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/1097-0142(196109\/10)14:5<901::AID-CNCR2820140502>3.0.CO;2-Q","article-title":"Life history of the carcinoid tumor of the small intestine","volume":"14","author":"Moertel","year":"1961","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.disamonth.2021.101304_bib0014","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0039-6109(16)40288-4","article-title":"Carcinoid syndrome","volume":"54","author":"Tilson","year":"1974","journal-title":"Surg Clin North Am"},{"issue":"4","key":"10.1016\/j.disamonth.2021.101304_bib0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0960-7404(01)00007-X","article-title":"Recent advances in carcinoid pathogenesis, diagnosis and management","volume":"9","author":"Ganim","year":"2000","journal-title":"Surg Oncol"},{"key":"10.1016\/j.disamonth.2021.101304_bib0016","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3332\/ecancer.2016.662","article-title":"Complications from carcinoid syndrome: review of the current evidence","volume":"10","author":"Mota","year":"2016","journal-title":"Ecancermedicalscience"},{"issue":"10","key":"10.1016\/j.disamonth.2021.101304_bib0017","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.amjcard.2004.01.075","article-title":"Carcinoid heart disease associated with primary ovarian carcinoid tumor","volume":"93","author":"Chaowalit","year":"2004","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.disamonth.2021.101304_bib0018","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/CIRCULATIONAHA.107.701367","article-title":"Carcinoid heart disease","volume":"116","author":"Bhattacharyya","year":"2007","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.disamonth.2021.101304_bib0019","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0011-3840(89)90010-5","article-title":"Carcinoid tumors and the carcinoid syndrome","volume":"26","author":"Feldman","year":"1989","journal-title":"Curr Probl Surg"},{"issue":"3","key":"10.1016\/j.disamonth.2021.101304_bib0020","first-page":"e7186","article-title":"Carcinoid syndrome: a review","volume":"12","author":"Gade","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2021.101304_bib0021","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1749-6632.1994.tb17296.x","article-title":"Metastatic carcinoid tumors and the malignant carcinoid syndrome","volume":"733","author":"Kvols","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"21","key":"10.1016\/j.disamonth.2021.101304_bib0022","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM199311183292131","article-title":"Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea [published correction appears in","volume":"329","author":"von der Ohe","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2021.101304_bib0023","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8341426","article-title":"Update on pathophysiology, treatment, and complications of carcinoid syndrome","volume":"2020","author":"Clement","year":"2020","journal-title":"J Oncol"},{"key":"10.1016\/j.disamonth.2021.101304_bib0024","series-title":"Endotext. South Dartmouth (MA)","article-title":"Carcinoid tumors","author":"Vinik","year":"2018"},{"issue":"7332","key":"10.1016\/j.disamonth.2021.101304_bib0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(64)92907-1","article-title":"Release of a kinin peptide in the carcinoid syndrome","volume":"1","author":"Oates","year":"1964","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.disamonth.2021.101304_bib0026","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/02841868909111212","article-title":"Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management","volume":"28","author":"Vinik","year":"1989","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.disamonth.2021.101304_bib0027","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1590\/S0004-27302005000500028","article-title":"Carcinoid syndrome: diagnosis and medical management","volume":"49","author":"van der Lely","year":"2005","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"Suppl 2","key":"10.1016\/j.disamonth.2021.101304_bib0028","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/annonc\/12.suppl_2.S95","article-title":"Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours","volume":"12","author":"Tomassetti","year":"2001","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.disamonth.2021.101304_bib0029","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ecl.2018.04.014","article-title":"New treatments for the carcinoid syndrome","volume":"47","author":"Loughrey","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"10.1016\/j.disamonth.2021.101304_bib0030","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/j.amjmed.2018.05.026","article-title":"Diagnostic dilemma: carcinoid syndrome","volume":"131","author":"Beri","year":"2018","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.disamonth.2021.101304_bib0031","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3109\/00365528708991954","article-title":"Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements","volume":"22","author":"Oberg","year":"1987","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.disamonth.2021.101304_bib0032","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jso.2930190409","article-title":"Metabolic acidosis in patients with the carcinoid syndrome: treatment with parachlorophenylalanine","volume":"19","author":"Feldman","year":"1982","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.disamonth.2021.101304_bib0033","series-title":"StatPearls. Treasure Island (FL)","article-title":"Carcinoid syndrome","author":"Pandit","year":"2021"},{"issue":"10","key":"10.1016\/j.disamonth.2021.101304_bib0034","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/hrt.2004.040329","article-title":"Carcinoid heart disease: presentation, diagnosis, and management","volume":"90","author":"Fox","year":"2004","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.disamonth.2021.101304_bib0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000507847","article-title":"Carcinoid heart disease: pathophysiology, pathology, clinical manifestations, and management","volume":"146","author":"Jin","year":"2021","journal-title":"Cardiology"},{"key":"10.1016\/j.disamonth.2021.101304_bib0036","article-title":"Carcinoid syndrome-induced ventricular tachycardia","author":"Rupp","year":"2016","journal-title":"Case Rep Cardiol"},{"issue":"12","key":"10.1016\/j.disamonth.2021.101304_bib0037","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1572-0241.2004.40507.x","article-title":"Carcinoid tumors and fibrosis: an association with no explanation","volume":"99","author":"Modlin","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.disamonth.2021.101304_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-4632.2004.01959.x","article-title":"Pellagra: dermatitis, dementia, and diarrhea","volume":"43","author":"Hegyi","year":"2004","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.disamonth.2021.101304_bib0039","first-page":"422","article-title":"Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation","volume":"66","author":"Russo","year":"2004","journal-title":"Psychosom Med"},{"issue":"2","key":"10.1016\/j.disamonth.2021.101304_bib0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/curroncol13020006","article-title":"Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group","volume":"13","author":"Maroun","year":"2006","journal-title":"Curr Oncol"},{"issue":"9","key":"10.1016\/j.disamonth.2021.101304_bib0041","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1373\/clinchem.2004.032151","article-title":"Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors","volume":"50","author":"Zeutenhorst","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.disamonth.2021.101304_bib0042","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0004563215613109","article-title":"Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement","volume":"53","author":"Adaway","year":"2016","journal-title":"Ann Clin Biochem"},{"issue":"8","key":"10.1016\/j.disamonth.2021.101304_bib0043","first-page":"2622","article-title":"Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones","volume":"82","author":"Nobels","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.disamonth.2021.101304_bib0044","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3390\/cancers4030777","article-title":"Neuroendocrine tumors of the lung","volume":"4","author":"Fisseler-Eckhoff","year":"2012","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.disamonth.2021.101304_bib0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.soc.2006.05.002","article-title":"Carcinoid tumors","volume":"15","author":"Sippel","year":"2006","journal-title":"Surg Oncol Clin N Am"},{"issue":"3","key":"10.1016\/j.disamonth.2021.101304_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.hoc.2007.04.006","article-title":"Imaging of neuroendocrine tumors","volume":"21","author":"Tamm","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"10.1016\/j.disamonth.2021.101304_bib0047","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/0959-8049(96)00241-9","article-title":"Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours","volume":"32A","author":"Taal","year":"1996","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.disamonth.2021.101304_bib0048","article-title":"Carcinoid syndrome: updates and review of current therapy","volume":"20","author":"Oleinikov","year":"2019","journal-title":"Current Treatment Opt Oncol"},{"issue":"7","key":"10.1016\/j.disamonth.2021.101304_bib0049","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/02841860310010547","article-title":"Carcinoid a comprehensive review","volume":"42","author":"Schnirer","year":"2003","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.disamonth.2021.101304_bib0050","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1080\/14656566.2016.1236916","article-title":"Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies","volume":"17","author":"Ito","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.disamonth.2021.101304_bib0051","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1987.5.10.1502","article-title":"Karnofsky memorial lecture. An odyssey in the land of small tumors","volume":"5","author":"Moertel","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.disamonth.2021.101304_bib0052","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11912-015-0492-7","article-title":"Octreotide and lanreotide in gastroenteropancreatic neuroendocrine tumors","volume":"18","author":"Pokuri","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.disamonth.2021.101304_bib0053","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1677\/erc.0.0110019","article-title":"Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas","volume":"11","author":"de Herder","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.disamonth.2021.101304_bib0054","doi-asserted-by":"crossref","unstructured":"[Hofland and Lamberts, 2003 ]. DOI:10.1210\/er.2000-0001","DOI":"10.1210\/er.2000-0001"},{"key":"10.1016\/j.disamonth.2021.101304_bib0055","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3748\/wjg.v21.i6.1945","article-title":"Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review","volume":"21","author":"Broder","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.disamonth.2021.101304_bib0056","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0959-8049(92)90389-J","article-title":"A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour","volume":"28","author":"Veenhof","year":"1992","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.disamonth.2021.101304_bib0057","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-14-0354","article-title":"GEP\u2013NETs UPDATE: biotherapy for neuroendocrine tumours","volume":"172","author":"Alonso-Gordoa","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.disamonth.2021.101304_bib0058","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/02841869109092413","article-title":"Treatment of gastrointestinal endocrine tumours with inter-feron-alpha and octreotide","volume":"30","author":"Creutzfeldt","year":"1991","journal-title":"Acta Oncol"},{"key":"10.1016\/j.disamonth.2021.101304_bib0059","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long- acting release in patients with metastatic neuroendo- crine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Dev Ther."},{"key":"10.1016\/j.disamonth.2021.101304_bib0060","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","article-title":"Interferon in the management of neuroen-docrine GEP-tumors: a review","volume":"62","author":"Oberg","year":"2000","journal-title":"Digestion"},{"key":"10.1016\/j.disamonth.2021.101304_bib0061","series-title":"Neuroendocrine Tumors In Sleisenger and Fordtran's Gastrointestinal and Liver Diseases","first-page":"501","author":"Jensen","year":"2016"},{"issue":"2","key":"10.1016\/j.disamonth.2021.101304_bib0062","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1471-4159.2004.02850.x","article-title":"Different prop-erties of the central and peripheral forms of human tryptophan hydroxylase","volume":"92","author":"McKinney","year":"2005","journal-title":"J Neurochem"},{"issue":"5","key":"10.1016\/j.disamonth.2021.101304_bib0063","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syn- drome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.disamonth.2021.101304_bib0064","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1634\/theoncologist.2015-0455","article-title":"Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors","volume":"21","author":"Molina-Cerrillo","year":"2016","journal-title":"Oncologist"},{"issue":"9130","key":"10.1016\/j.disamonth.2021.101304_bib0065","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(98)02286-7","article-title":"Carcinoid tumour","volume":"352","author":"Caplin","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.disamonth.2021.101304_bib0066","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000085237","article-title":"Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours","volume":"80","author":"Plockinger","year":"2005","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.disamonth.2021.101304_bib0067","first-page":"317","article-title":"Surgical management of gastro-intestinal carcinoid tumors","volume":"28","author":"Loftus","year":"1995","journal-title":"Adv Surg"},{"key":"10.1016\/j.disamonth.2021.101304_bib0068","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0003-4975(94)00630-P","article-title":"Carcinoid tumors of the lung: do atypical features require aggressive management?","volume":"59","author":"Marty-Ane","year":"1995","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.disamonth.2021.101304_bib0069","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0360-3016(91)90061-8","article-title":"The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors","volume":"20","author":"Schupak","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.disamonth.2021.101304_bib0070","first-page":"441","article-title":"Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors","volume":"52","author":"Khan","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.disamonth.2021.101304_bib0071","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3892\/mco.2016.1097","volume":"6","author":"Faure","year":"2016","journal-title":"Mol Clin Oncol"},{"issue":"21","key":"10.1016\/j.disamonth.2021.101304_bib0072","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJM196711232772101","article-title":"Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome","volume":"277","author":"Engelman","year":"1967","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.disamonth.2021.101304_bib0073","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/jpet.107.132670","article-title":"Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract","volume":"325","author":"Liu","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"10.1016\/j.disamonth.2021.101304_bib0074","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1007\/s00259-015-3155-x","article-title":"The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis","volume":"42","author":"Kim","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.disamonth.2021.101304_bib0075","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.disamonth.2021.101304_bib0076","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.disamonth.2021.101304_bib0077","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/SLA.0b013e318288ff6d","article-title":"Cognitive impairment associated with carcinoid syndrome","volume":"259","author":"Pasieka","year":"2014","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.disamonth.2021.101304_bib0078","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.amjcard.2007.08.045","article-title":"Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century","volume":"101","author":"Bhattacharyya","year":"2008","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.disamonth.2021.101304_bib0079","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"69","author":"Davar","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.disamonth.2021.101304_bib0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000440621","article-title":"Niacin (vitamin B3) supplementation in patients with serotonin-producing neuroendocrine tumor","volume":"103","author":"Bouma","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.disamonth.2021.101304_bib0081","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/MPA.0b013e318271c0d5","article-title":"A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs)","volume":"42","author":"Tellez","year":"2013","journal-title":"Pancreas"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502921001802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502921001802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T01:02:30Z","timestamp":1757898150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502921001802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0011502921001802"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2021.101304","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in the Diagnosis and Management of Carcinoid Syndrome","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2021.101304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101304"}}